LUPRON DEPOT-PED KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LUPRON DEPOT-PED KIT (LUPRON DEPOT-PED KIT).
Leuprolide acetate, a GnRH agonist, initially stimulates pituitary gonadotropin release, but chronic administration suppresses LH and FSH secretion by downregulation of GnRH receptors, leading to reduced sex steroid production.
| Metabolism | Metabolized primarily by hydrolysis of the C-terminal amino acids to pentapeptide and tetrapeptide metabolites; not significantly metabolized by CYP450 enzymes. |
| Excretion | Renal (approximately 50% as unchanged drug and 50% as inactive metabolites); biliary/fecal excretion accounts for <5% |
| Half-life | Terminal elimination half-life is approximately 3 hours following subcutaneous administration; however, due to the depot formulation, the effective half-life is extended to about 1 month, driven by the slow release from the PLGA microspheres. |
| Protein binding | Approximately 46–50% bound to sex hormone-binding globulin (SHBG) and albumin in plasma. |
| Volume of Distribution | Volume of distribution (Vd) is approximately 0.3 L/kg, indicating distribution primarily into extracellular fluid and tissues with low intracellular penetration. |
| Bioavailability | Subcutaneous: Following depot injection, bioavailability is essentially 100% due to the controlled-release formulation; the mean peak serum concentration is achieved at approximately 1–2 hours post-injection, with sustained release over 4 weeks. |
| Onset of Action | Subcutaneous: Suppression of gonadotropin secretion occurs within 2–4 weeks after the first injection; GnRH agonist flare effect may be observed in the first week. |
| Duration of Action | After a single depot injection, therapeutic suppression of pituitary gonadotropins (LH, FSH) persists for at least 4 weeks, supporting monthly dosing intervals; maximal suppression is maintained with continued monthly administration. |
| Molecular Weight | 1269.47 |
Leuprolide acetate 3.75 mg IM monthly or 11.25 mg IM every 3 months; for central precocious puberty, 7.5 mg IM monthly or 22.5 mg IM every 3 months.
| Dosage form | POWDER |
| Renal impairment | No specific GFR-based dose modifications recommended; clinical monitoring advised. |
| Liver impairment | No specific Child-Pugh based modifications recommended; caution in moderate to severe impairment. |
| Pediatric use | Central precocious puberty: 7.5 mg IM monthly (weighing <25 kg) or 11.25 mg IM monthly (weighing ≥25 kg); 45 mg 6-month depot available; initiate at diagnosis and titrate to suppress pubertal development. |
| Geriatric use | No specific dose adjustment required; monitor for cardiovascular risk and bone density loss due to prolonged androgen deprivation. |
| 1st trimester | Potential risk of miscarriage and congenital anomalies, particularly with exposure during the critical period of organogenesis. Not recommended for use in pregnancy. |
| 2nd trimester | Continue to avoid use due to potential fetal harm, including possible effects on fetal sexual development and other teratogenic risks. |
| 3rd trimester | Avoid use; may cause fetal harm or adverse effects on fetal development. |
Clinical note
Comprehensive clinical and safety monograph for LUPRON DEPOT-PED KIT (LUPRON DEPOT-PED KIT).
| Placental transfer | Leuprolide crosses the placenta; studies have shown transfer to fetal circulation in animal models. |
| Breastfeeding | Leuprolide is excreted in human milk; because of the potential for serious adverse reactions in nursing infants, a decision should be made either to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. |
■ FDA Black Box Warning
None.
| Serious Effects |
PregnancyHypersensitivity to leuprolide acetate or any component of the formulationUndiagnosed vaginal bleeding
| Precautions | Initial transient stimulation of sex steroids may cause temporary worsening of signs and symptoms of CPP., May cause pseudotumor cerebri (idiopathic intracranial hypertension) and convulsions., Monitor bone mineral density; risk of decreased bone density with prolonged use., Hypersensitivity reactions including anaphylaxis have been reported., Injection site reactions may occur. |
| Food/Dietary | No significant food interactions. May be taken without regard to meals. Alcohol does not interact. |
Loading safety data…
| Lactation Rating | L4 (possibly hazardous) |
| Teratogenic Risk | First trimester: Theoretical risk of spontaneous abortion and congenital anomalies based on leuprolide's mechanism (GnRH agonist); data limited. Second/third trimester: Not indicated for use; fetal risk cannot be excluded due to hormonal interference. |
| Fetal Monitoring | Monitor pregnancy test before each injection. Assess for signs of fetal development abnormalities if inadvertent exposure occurs; no specific monitoring mandated. |
| Fertility Effects | Reversible suppression of pituitary-gonadal axis; oligospermia or anovulation may occur. Fertility returns after discontinuation; no permanent impairment in studies. |
| Clinical Pearls |
| Lupron Depot-Ped (leuprolide acetate) is a GnRH agonist used for central precocious puberty (CPP). Initial administration may cause a transient increase in gonadotropins and sex steroids ('flare' effect) lasting 2-4 weeks, potentially causing temporary worsening of pubertal signs. Monitor for sterile abscess formation at injection site due to depot formulation; rotate sites. Assess growth velocity, bone age, and Tanner staging every 3-6 months. Discontinue by age 11 (girls) or 12 (boys) to allow pubertal progression. Contraindicated in pregnancy due to risk of fetal harm. |
| Patient Advice | This medication is given as an injection every 1, 3, or 6 months by a healthcare provider. · During the first few weeks, you may notice temporary worsening of puberty symptoms (e.g., breast enlargement, vaginal bleeding, erections). This is expected and will subside. · Report any injection site reactions (pain, redness, swelling, or lumps) to your doctor. · Keep all appointments for follow-up growth checks and bone age X-rays. · Do not stop treatment without consulting your doctor; irregular dosing may cause return of puberty. · This medication can cause harm to an unborn baby. Use effective contraception if sexually active. · Store unused kits in the refrigerator; do not freeze. Keep out of reach of children. |